![]() |
市场调查报告书
商品编码
1827773
2025年全球预填充式注射器市场报告Pre Filled Syringes Global Market Report 2025 |
近年来,预填充式注射器市场快速扩张,市场规模从2024年的83亿美元成长至2025年的93.9亿美元,复合年增长率为13.1%。预测期内的成长归因于製药和生物技术行业的成长、生技药品和疫苗的扩张、对用户友好且精准给药的需求、家庭医疗保健和自我给药的兴起,以及药品安全和包装监管标准的提高。
预计未来几年预填充式注射器市场将快速成长,到2029年将达到160.9亿美元,年复合成长率(CAGR)为14.4%。预测期内的增长可归因于针对特定药物定制的预填充式注射器解决方案、可生物降解和永续材料的扩展、联网和智能注射器的创新、远端医疗和远端医疗应用的增加以及长效注射剂的采用。预测期内的主要趋势包括预填充式注射器安全性方面的法规合规性、用于精确剂量的智慧连网注射器、可生物降解和环保的注射器材料、针对患者群体定制的注射器解决方案以及药物输送的透明度和可追溯性。
预填充式注射器是一种预先填充了要注射的物质的注射器,可以更容易地将内容物精确地输送到所需位置。
预填充式注射器主要分为传统预填充式注射器和安全预填充式注射器。传统预填充式注射器通常装有单剂量疫苗,并配有製造商固定的一次性针头。注射后,注射器即被丢弃。而安全预填充式注射器则装有单剂量疫苗,供需要定期在家注射的病人自行注射。这些注射器的针头由玻璃或塑胶等材料製成,且注射器有多种形状,包括单室预填充式注射器、双室预填充式注射器和客製化预填充式注射器。这些预填充式注射器用于治疗多种疾病,包括糖尿病、类风湿性关节炎、过敏反应、癌症、血栓症和眼科疾病。
2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响,尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制价格上涨,製造商面临利润压力。监管挑战使情况更加复杂,因为由于关税而更换供应商通常需要重新认证医疗设备,导致市场进入延迟。为此,企业正在透过双重采购关键零件、增加标准产品的国内生产以及加快寻找更具成本效益的材料来降低风险。
本研究报告是商业研究公司 (The Business Research Company) 最新报告系列之一,提供预充式註射器市场统计数据,包括全球预充式预填充式注射器行业预填充式注射器、各地区市场份额、竞争对手的市场份额、预填充式注射器预填充式注射器市场的细分市场、市场趋势和商机,以及在预填充式注射器行业取得成功所需的数据。预填充式注射器市场研究报告对产业现状和未来趋势进行了详细分析,为您提供所需的全方位观点。
我们预测未来五年该市场将成长14.4%,较先前预测略有下降0.3%。下降主要源自于美国与其他国家之间关税的影响。美国将直接感受到关税的影响,包括玻璃桶模和硅胶润滑系统(以及来自巴西和丹麦的关键进口产品)的供应链中断,这可能导致疫苗和生物製药的交付延迟。此外,互惠关税以及贸易紧张局势和限制措施升级对全球经济和贸易的负面影响也将更广泛地体现在关税上。
由于家庭医疗保健的重要性日益增加,预计预填充式注射器市场将在预测期内经历显着成长。居家医疗为居家患者提供医疗照护和支持,旨在促进患者康復、管理疾病并提供便利的照护。随着医疗保健格局的变化,包括对精准给药、最大限度降低污染风险和提高患者依从性的需求,预计预填充式注射器市场将大幅扩张。这有助于提高患者在家中舒适护理的品质。例如,根据美国居家照护和临终关怀协会 2023 年 2 月发布的数据,每年约有 1,200 万美国人接受居家医疗,预计这一数字还将继续增加。因此,预计家庭医疗保健的快速成长将在预测期内推动市场成长。
癌症治疗需求的不断增长预计将推动预填充式注射器市场的成长。肿瘤治疗包括用于诊断、管理和治疗癌症的医疗程序和治疗方法,例如手术、化疗、放射线治疗、免疫疗法和标靶治疗。癌症盛行率的上升、治疗方法的进步、早期检测方法的改进以及人口老化等因素推动了需求的增长,所有这些因素都推动了对有效癌症治疗的需求。预填充式注射器在癌症治疗中发挥关键作用,它能够提供准确、即用型的化疗和生物製药剂量,简化给药流程并提高患者依从性。例如,根据英国慈善机构麦克米伦癌症援助组织的数据,该组织旨在提供实际、情感和经济支持,以改善癌症患者的生活质量,目前英国癌症患者数量已超过 300 万,预计到 2025 年将达到 350 万,到 2030 年将达到 400 万,到 2040 年将达到 530 万。因此,对癌症治疗的不断增长的需求预计将推动预填充式注射器市场的成长。
预填充式注射器市场的公司正加大对新一代预填充式注射器的投资,这些注射器具备允许医护人员追踪和存取资料的功能。新一代预填充式注射器是指技术先进的注射器,旨在增强药物输送、提高病人安全性,并提供连接性和易用性等附加功能。 2022年9月,美国医疗科技公司碧迪公司 (BD) 推出了新一代玻璃预填充式注射器,旨在满足严格的可加工性、外观、完整性和污染标准。这款名为 BD Effivax 玻璃预灌封注射器的创新註射器是与一家领先的製药公司合作开发的,旨在满足不断变化的疫苗生产需求。
为了扩大其在医疗保健领域的影响力,预填充式注射器市场的领先医疗保健公司正在寻求单剂量预填充式注射器等创新产品的核准。单剂量预填充式注射器是预先装有註射药物的一次性注射器,为治疗给药提供了便捷的解决方案。例如,2023年3月,美国食品药物管理局(FDA)批准了美国製药公司Nexus Pharmaceuticals Inc.生产的Emerphed(硫酸麻黄碱注射液)25毫克/5毫升和50毫克/10毫升单剂量预填充式注射器。这是FDA首次核准10毫升(mL)容量的硫酸麻黄碱注射用核准预填充式注射器。
2022年1月,荷兰製药公司北欧製药 (Nordic Pharma BV) 从赛诺菲 (Sanofi) 手中收购了 ALTIM预填充式注射器的专利。此次收购旨在增强北欧製药在风湿病领域的产品组合。该公司计划优化该产品的生产工艺,并将其重新推向市场,以满足临床医生对该治疗方案的持续需求。赛诺菲是一家总部位于法国的製药和医疗保健公司。
预填充式注射器市场的主要公司包括 Becton, Dickinson and Company、Gerresheimer AG、Schott & Associates Glass Technology Laboratory、West Pharmaceutical Services Inc.、Baxter International、Nipro Corporation、Terumo Corporation、Vetter Pharma International GmbH、Stevanato Group SPA、山东威高集团医疗用高分子材料有限公司、Voltis. AG、Pfizer Inc.、Bristol-Myers Squibb Co.、Hoffmann-La Roche、AbbVie, Inc.、Owen Mumford Holdings, Inc.、 Medtronic, Inc.、Medtronic, Inc.、Abbott Laboratories, Inc.、Fresen Kabi Nabi Ltd.、Medical Protec告诉Medical、ACASI Machinery Inc.、Bespak Holdings Ltd. 和 BioPharma Solutions、Catalent Pharma解决方案、Credence MedSystems Inc.、Hasemeier Inc.、Intas Pharmaceuticals Ltd.、Intelicure Lifesciences、Mycoscience Labs
2024 年,欧洲是预填充式注射器市场最大的地区。预填充式注射器市场分析报告涵盖的地区包括亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
预填充式注射器市场报告涉及的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国和美国。
预填充式注射器市场包括玻璃预填充式注射器和塑胶预填充式注射器的销售。该市场的价值是“出厂价”,即商品製造商或生产商销售给其他营业单位(包括下游製造商、批发商、经销商和零售商)或直接销售给最终客户的价值。该市场中的商品价值还包括商品製造商销售的任何相关服务。
Pre-filled syringes refer to syringes that come pre-loaded with the substance intended for injection, facilitating the accurate delivery of the contents to the desired location.
The primary types of pre-filled syringes include conventional pre-filled syringes and safety pre-filled syringes. Conventional pre-filled syringes typically contain a single-dose packet of vaccines, with a manufacturer-fixed needle designed for one-time use. After application, the syringe is disposed of. Safety pre-filled syringes, on the other hand, contain a single-dose packet of vaccine intended for self-administration by patients who require regular injections in a home setting. Needles for these syringes are crafted from materials such as glass and plastic, and the syringes come in various forms, including single-chamber pre-filled syringes, dual-chamber pre-filled syringes, and customized pre-filled syringes. These pre-filled syringes find applications in a range of medical conditions such as diabetes, rheumatoid arthritis, anaphylaxis, cancer, thrombosis, ophthalmology, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The pre-filled syringes market research report is one of a series of new reports from The Business Research Company that provides pre-filled syringes market statistics, including pre-filled syringes industry global market size, regional shares, competitors with a pre-filled syringes market share, detailed pre-filled syringes market segments, market trends and opportunities and any further data you may need to thrive in the pre-filled syringes industry. The pre-filled syringe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pre filled syringes market size has grown rapidly in recent years. It will grow from $8.3 billion in 2024 to $9.39 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to growth in the pharmaceutical and biotechnology industry, expansion of biologics and vaccines, demand for user-friendly and precise drug delivery, increase in home healthcare and self-administration, regulatory standards for drug safety and packaging.
The pre filled syringes market size is expected to see rapid growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to customized pre-filled syringe solutions for specific drugs, expansion of biodegradable and sustainable materials, innovation in connected and smart syringes, increased use in telemedicine and telehealth, adoption in long-acting injectable medications. Major trends in the forecast period include regulatory compliance in pre-filled syringe safety, smart and connected syringes for precise dosing, biodegradable and eco-friendly syringe materials, personalized syringe solutions for patient populations, transparency and traceability in drug delivery.
The forecast of 14.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for glass barrel molds and silicone lubrication systems, key imports from Brazil and Denmark, delaying vaccine and biologic drug delivery.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The pre-filled syringe market is anticipated to experience significant growth due to the increasing prominence of home-based healthcare during the forecast period. Home-based healthcare involves providing medical treatment and support to patients in their residences, aiming to facilitate recovery, manage illnesses, and deliver care in the convenience of patients' homes. The pre-filled syringe market is poised for substantial expansion, aligning with the changing healthcare landscape by ensuring precise dosing, minimizing contamination risks, and enhancing patient compliance. This contributes to an elevated quality of care delivered within the comfort of patients' homes. For example, data from the National Association for Home Care and Hospice in February 2023 reveals that around 12 million Americans annually receive home healthcare, with this number expected to continue growing. Hence, the surge in home-based healthcare is anticipated to drive market growth in the forecast period.
The increasing demand for oncology treatment is anticipated to drive growth in the pre-filled syringe market. Oncology treatment encompasses the medical care and therapies employed to diagnose, manage, and treat cancer, including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies. This heightened demand is fueled by the growing prevalence of cancer, advancements in treatment options, enhanced early detection methods, and a rising aging population, all of which lead to a greater need for effective cancer care. Pre-filled syringes play a crucial role in oncology treatment by providing precise, ready-to-use doses of chemotherapy agents and biologic therapies, simplifying administration, and enhancing patient compliance. For example, according to Macmillan Cancer Support, a UK-based charity dedicated to providing practical, emotional, and financial assistance to those affected by cancer to improve their quality of life, the number of individuals living with cancer in the UK is projected to surpass 3 million currently, reaching 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising demand for oncology treatment will propel the growth of the pre-filled syringe market.
Companies operating in the pre-filled syringes market are increasingly investing in next-generation prefilled syringes, incorporating features that enable healthcare professionals to track and access data. Next-generation pre-filled syringes refer to technologically advanced syringes designed to enhance drug delivery, elevate patient safety, and provide additional features like connectivity and usability. In September 2022, Becton, Dickinson and Company (BD), a US-based medical technology company, introduced a next-generation glass prefillable syringe designed to meet rigorous standards for processability, cosmetics, integrity, and contamination. This innovative syringe, known as BD Effivax Glass Prefillable Syringe, was developed in collaboration with leading pharmaceutical companies to address the evolving requirements of vaccine production.
Leading healthcare companies in the pre-filled syringe market are seeking approval for innovative products, such as single-dose pre-filled syringes, to broaden their presence in the healthcare sector. Single-dose pre-filled syringes, which contain a disposable syringe preloaded with medication liquid for injection, offer a convenient solution for administering treatments. For example, in March 2023, the Food and Drug Administration (FDA) granted approval for Emerphed (ephedrine sulfate injection) in 25 mg/5 mL and 50 mg/10 mL single-dose pre-filled syringes manufactured by Nexus Pharmaceuticals Inc., a US-based pharmaceutical company. This marks the FDA's approval of the first 10-milliliter (mL) pre-filled syringe for ephedrine sulfate injection.
In January 2022, Nordic Pharma B.V., a pharmaceutical company based in the Netherlands, acquired the rights to the ALTIM pre-filled syringe from Sanofi. This acquisition aims to strengthen Nordic Pharma's portfolio in the rheumatology sector. The company intends to optimize the manufacturing process of the product to reintroduce it to the market, addressing the ongoing demand from clinicians for this treatment option. Sanofi S.A. is a pharmaceutical and healthcare company headquartered in France.
Major companies operating in the pre filled syringes market include Becton, Dickinson and Company, Gerresheimer AG, Schott & Associates Glass Technology Laboratory, West Pharmaceutical Services Inc., Baxter International, Nipro Corporation, Terumo Corporation, Vetter Pharma International GmbH, Stevanato Group SPA, Shandong Weigao Group Medical Polymer Company Ltd., Novartis AG, Catalent Inc., Unilife Corporation, Eli Lilly and Company, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., AbbVie Inc., Owen Mumford Holdings Ltd., AptarGroup Inc., Medtronic Plc, Abbott Laboratories, Fresenius Kabi India Pvt. Ltd., Medical Protective Ltd., Mylan NV, Elcam Medical Inc., YPSOMED Holding AG, Oval Medical Technologies, SHL Medical, ACASI Machinery Inc., Bespak Holdings Ltd., BioPharma Solutions, Catalent Pharma Solutions, Credence MedSystems Inc., Hasemeier Inc., Intas Pharmaceuticals Ltd., Intelicure Lifesciences, Mycoscience Labs
Europe was the largest region in the prefilled syringes market in 2024. The regions covered in the prefilled syringes market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the pre-filled syringes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The pre-filled syringes market consists of sales of glass prefilled syringes and plastic prefilled syringes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pre Filled Syringes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pre filled syringes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pre filled syringes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pre filled syringes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.